

## H1 sales up +33% (1,6 M€), reflecting first results of strategic roadmap

- Increased activity driven by france and europe
- New product developments and innovations for comprehensive patient follow-up
- Continued growth outlook and expansion into new markets

Montpellier, France, July 24, 2025, 5 :45 PM. **Intrasense (ISIN : FR0011179886 – Mnémo : ALINS)**, a French expert in AI-enhanced medical imaging solutions that facilitate and secure diagnosis, decision-making, and therapeutic follow-up, announces its consolidated sales for the first half of fiscal year 2025.

IFRS sales	Published data			At constant exchange rates	
Year	2024	2025	Change	2025	Change
1 <sup>st</sup> half-year	1 203	1 603	+33,2%	1 601	+33,1%

In the first half of the year, Intrasense reportes a +33.2% increase in consolidated revenue (€1.6M) compared to H1 2024. Sequentially, compared to H2 2024 (€1.0M), revenue grew by +60%.

### Strong revenue growth driven by europe and france

IFRS sales	Published data			At constant exchange rates	
H1	2024	2025	Change	2025	Change
France	444	553	+24,6%	553	+24,6%
Europe	144	545	+279,5%	545	+279,5%
China	245	129	-47,5%	127	-48,2%
Other regions	370	376	+1,5%	376	+1,6%
<b>TOTAL</b>	<b>1 203</b>	<b>1 603</b>	<b>+33,2%</b>	<b>1 601</b>	<b>+33,1%</b>

Key geographic trends in H1 2025:

- In Europe, business is growing strongly, up 279.5% (€545K), driven mainly by sales from our manufacturing and distribution partners.
- In France, business is up 24.6% (€553K). These sales are mainly direct (new licenses or maintenance contracts). This region is benefiting from the first sales of AI applied to the detection of lung nodules.
- In "other regions," business remained stable at €376K (+1.5%) and was mainly driven by sales from our PACS publisher partners.
- In China, in line with the roadmap announced in March<sup>1</sup>, sales were down -47.5% (€129K).

## A structured and growing ai-driven offering supporting patients across the care pathway

With its three product lines, Intrasense supports patients throughout their care journey:

- Daily imaging (Myrian®),
- Lesion detection (DUOnco™),
- Oncology follow-up (Liflow®).

Following the certification of six major solutions in 2024, Intrasense has made further product advances in the first half of this year:

- **DUOnco™ Bone** was the first CE-marked<sup>2</sup> AI algorithm for detecting bone lesions on CT scans. A world first with a major impact on oncology imaging, this solution was eagerly awaited by the medical sector.
- **DUOnco™ Pancreas** has been granted Breakthrough Device status by the US Food and Drug Administration (FDA). Developed in partnership with Guerbet, this solution aims to improve the detection of pancreatic cancer in patients, which remains one of the deadliest forms of cancer in the United States. In Europe, CE marking for this solution is planned for the second half of 2025.
- **Liflow® 3.0** obtained CE<sup>2</sup> marking in July 2025. The solution dedicated to oncology monitoring now includes an algorithm for detecting bone lesions, in addition to those for the liver and lungs. This new version also introduces automatic exam realignment for smoother comparative reading, as well as lesion sorting by size to more quickly target major abnormalities.
- **Myrian® 2.14** obtained CE<sup>2</sup> certification in March 2025, providing specific updates in breast imaging, particularly for tomosynthesis reading.

## Outlook: h2 2025 brings new commercial opportunities

As in 2024, Intrasense will be present at the most important radiology events. These include:

- The French Radiology Days (JFR), where the company won the 2024 Innovation Award in the "Health IT and AI" category for its Liflow solution.

<sup>1</sup> See press release dated March 26, 2025.

<sup>2</sup> Sous règlement MDR (2017/745)

- The Annual Meeting of the Radiological Society of North America (RSNA), the world's largest radiology conference.

These events offer strong commercial potential, as the showcased Intrasense solutions are already highly endorsed by the medical community.

In addition, Intrasense aims to integrate its solutions into new marketplaces in the second half of the year in order to market its products in new markets and new areas in line with its **geographical expansion strategy**.

Finally, as previously announced, Intrasense is approaching the second half of the year with confidence, aiming to achieve **double-digit annual sales growth compared to 2024**. This favorable outlook for business growth will be accompanied by continued strict cost control.

### Next financial announcement:

2025 half-year results: September 24 (after market close)

## About Intrasense

A French expert in medical imaging since 2004 and a digital subsidiary of the Guerbet Group, Intrasense designs medical imaging software solutions natively enriched by artificial intelligence algorithms.

Myrian®, an advanced radiology visualization platform featuring cutting-edge clinical tools, optimizes and simplifies the interpretation of all types of images. DUOnco™, a range of expert AI algorithms for oncology, offers an AI for the detection of focal liver lesions and the first AI dedicated to CE-marked bone lesions. Liflow®, a dedicated oncology monitoring solution integrating multi-organ AIs, optimizes the longitudinal monitoring of cancer patients.

By combining clinical expertise and operational performance, Intrasense provides healthcare professionals with high medical value tools, facilitating analysis, diagnosis and patient management.

More information on [www.intrasense.fr](http://www.intrasense.fr)

## Contacts

### INTRASENSE

Communication officer

Salomé Sylvestre

Phone : +33 4 67 13 01 30

[investisseurs@intrasense.fr](mailto:investisseurs@intrasense.fr)

### SEITOSEI.ACTIFIN

Analyst & Investor Relations

Foucauld Charavay

Phone : +33 6 37 83 33 19

[intrasense@seitosei-actifin.com](mailto:intrasense@seitosei-actifin.com)

### Press Relations

Isabelle Dray

Phone : +33 1 56 88 11 29

[isabelle.dray@seitosei-actifin.com](mailto:isabelle.dray@seitosei-actifin.com)